The application of inhibitors of mTOR and other regulators implicated in NAFLD/NASH helped us better understand its orchestrating role and further allowed the discovery of novel potential biomarkers in NAFLD/NASH and HCC. Here, MTOR is linked to metabolic dysfunction-associated steatohepatitis.